natgillin/translations-raw huggingface dataset:
Target organs for neoplastic changes were the kidneys, urinary bladder, urethra, preputial and clitoral gland, small intestine, parathyroid glands, adrenal glands and non-glandular stomach.
Tarčni organi za neoplastične spremembe so bili: ledvice, sečni mehur, sečnica, žleze prepucija in klitorisa, tanko črevo, obščitnične žleze, nadledvične žleze in ne
Renal insufficiency: Patients with renal dysfunction or on dialysis should be given the minimum recommended dose of 400 mg daily as starting dose.
Bolniki s poslabšanim delovanjem ledvic ali bolniki na dializi naj za začetni odmerek prejmejo najmanjši priporočeni odmerek 400 mg na dan.
- if you have ever had or might now have a hepatitis B infection.
- če ste kdaj bili ali ste sedaj okuženi z virusom hepatitisa B. Zdravilo Imatinib Teva B.V.
Dizziness, paraesthesia, taste disturbance, hypoaesthesia Migraine, somnolence, syncope, peripheral neuropathy, memory impairment, sciatica, restless leg syndrome, tremor, cerebral haemorrhage Increased intracranial pressure, convulsions, optic neuritis
vrtoglavost, parestezije, motnje okušanja, hipestezije migrena, somnolenca, sinkopa, periferna nevropatija, motnje spomina, išias, sindrom nemirnih nog, tremor, možganska krvavitev zvišan intrakranialni tlak, konvulzije, optični nevritis možganski edem*
Out of the 12 patients enrolled, 9 responded, one completely and 8 partially.
bolnikih, pri enem do popolnega in pri 8 do delnega.
Figure 2 Kaplan-Meier estimates for overall survival (ITT population)
Ocena celotnega preživetja po Kaplan-Meierjevi metodi (populacija z namenom število tveganju izpostavljenih bolnikov : število dogodkov
600 mg)
(začetni odmerek 600 mg)
There were no special safety findings in paediatric clinical trials.
V pediatričnih kliničnih preskušanjih ni bilo
The plasma protein binding of the N-demethylated metabolite is similar to that of the parent
Vezava N-demetiliranega presnovka na plazemske beljakovine je podobna kot pri izhodni spojini.
Newly diagnosed Ph+ ALL: In a controlled study (ADE10) of imatinib versus chemotherapy induction in 55 newly diagnosed patients aged 55 years and over, imatinib used as single agent induced a significantly higher rate of complete haematological response than chemotherapy (96.3% vs. 50%; p=0.0001).
V kontrolirani študiji (ADE10) imatiniba v primerjavi z indukcijo s kemoterapijo pri 55 bolnikih z novo odkrito boleznijo, ki so bili stari 55 let ali več, je imatinib kot edino zdravilo povzročil značilno večji delež bolnikov s popolnim hematološkim odzivom kot kemoterapija (96,3 % v primerjavi s 50
Patients with cardiac disease, risk factors for cardiac failure or history of renal failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac or renal failure should be evaluated
Srčne bolnike, bolnike z dejavniki tveganja za odpoved srca ali bolnike z anamnezo ledvične odpovedi je potrebno skrbno opazovati.
Paediatric accelerated phase CML and blast crisis (starting dose 340 mg/m2)
kronična faza KML pri pediatričnih bolnikih (ob odmerku 340 mg/m2)
(24 h), day 1;
(24 ur), 1. dan,
Therefore, caution should be exercised in patients with cardiac
Zato je pri bolnikih z motnjami delovanja srca potrebna previdnost.
If cytopenia persists for 4 weeks and is still unrelated to leukaemia, stop Imatinib until
tedne in še vedno ni povezana z levkemijo, prekinite zdravljenje z imatinibom,
• Sudden swelling and redness of the skin (signs of a skin infection called cellulitis).
• otrpli ali hladni prsti (znaki Raynaudovega sindroma), • nenadna oteklina in pordelost kože (znaki kožne okužbe z imenom flegmona (celulitis)),
The amount of Imatinib Teva B.V. given will depend on your child's condition, body weight and height.
bo odvisna od otrokovega stanja, telesne mase in višine.
Prednisolone 60 mg/m2/day oral Alternating chemotherapy course: high dose chemotherapy with MTX 1 g/m2 i.v.
prednizolon 60 mg/m2/dan peroralno izmenična kemoterapija: visokoodmerna kemoterapija z i.v.
6400 mg (single dose): One case reported in the literature of one patient who experienced nausea, vomiting, abdominal pain, pyrexia, facial swelling, decreased neutrophil count, increased transaminases.
Odmerek 6400 mg (enkraten odmerek): v literaturi je opisan en primer pri enem bolniku, pri katerem je prišlo do navzee, bruhanja, bolečin v trebuhu, zvišane telesne temperature, otekanja v obraz,
Imatinib Teva B.V. is a medicine containing an active substance called imatinib.
je zdravilo, ki vsebuje učinkovino z imenom imatinib.
Dose increases from 600 mg to a maximum of 800 mg (given as 400 mg twice daily) in patients with blast crisis may be considered in the absence of severe adverse drug reaction and severe non-leukaemia-related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory haematological response after at least 3 months of treatment; failure to achieve a cytogenetic response after 12 months of treatment; or loss of a previously achieved haematological and/or cytogenetic response.
Povečanje odmerka s 600 mg na največ 800 mg (odmerjanih po 400 mg dvakrat na dan) pri bolnikih v blastni krizi lahko pride v poštev, če bolnik nima hude neželene reakcije na zdravilo in hude nevtropenije ali trombocitopenije, ki ni povezana z levkemijo, v sledečih okoliščinah: napredovanje bolezni (kadarkoli); odsotnost zadovoljivega hematološkega odziva po najmanj 3 mesecih zdravljenja;
G-CSF = granulocyte colony stimulating factor, VP-16 = etoposide, MTX = methotrexate, IV = intravenous, SC = subcutaneous, IT = intrathecal, PO = oral, IM = intramuscular, ARA-C = cytarabine, CPM = cyclophosphamide, VCR = vincristine, DEX = dexamethasone, DAUN = daunorubicin, 6-MP = 6mercaptopurine, E.Coli L-ASP = L-asparaginase, PEG-ASP = PEG asparaginase, MESNA= 2mercaptoethane sulfonate sodium, iii= or until MTX level is < 0.1 µM, q6h = every 6 hours, Gy= Gray
= intramuskularno, ARA-C = citarabin, CPM = ciklofosfamid, VCR = vinkristin, DEX = deksametazon, DAUN = daunorubicin, 6-MP = 6-merkaptopurin, E.Coli L-ASP = L-asparaginaza, PEG-ASP = PEG asparaginaza, MESNA= natrijev 2-merkaptoetan sulfonat, iii= oziroma dokler koncentracija MTX ni
Relapsed/refractory Ph+ ALL: When imatinib was used as single agent in patients with relapsed/refractory Ph+ ALL, it resulted, in the 53 out of 411 patients evaluable for response, in a haematological response rate of 30% (9% complete) and a major cytogenetic response rate of 23%.
Zdravljenje z imatinibom kot edinim zdravilom pri bolnikih z relapsom/neodzivno Ph+ ALL je povzročilo pri 53 od 411 za oceno odziva primernih bolnikov stopnjo hematološkega odziva 30 % (v 9 % popolni hematološki odziv) in stopnjo pomembnega citogenetičnega odziva 23 %.
For CML and GIST, your doctor may prescribe a higher or lower dose depending on how you respond to the treatment.
Pri zdravljenju KML ali GIST vam lahko zdravnik predpiše večji ali manjši odmerek, odvisno od tega,
Caution should be used when taking imatinib with protease inhibitors, azole antifungals, certain macrolides (see section 4.5), CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporine, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel, quinidine) or warfarin and other coumarin derivatives (see section 4.5).
Previdnost je potrebna pri uporabi imatiniba z zaviralci proteaze, azolnimi antimikotiki, določenimi makrolidi, s substrati CYP3A4 z ozkim terapevtskim oknom (na primer s ciklosporinom, pimozidom, takrolimusom, sirolimusom, ergotaminom, diergotaminom, fentanilom, alfentanilom, terfenadinom, bortezomibom, docetakselom, kinidinom) ali z varfarinom in drugimi derivati kumarina (glejte poglavje 4.5).
The age of these patients ranged from 8 to 18 years and imatinib was given in both adjuvant and metastatic settings at doses ranging from 300 to 800 mg daily.
Ti bolniki so bili stari od 8 do 18 let, imatinib pa so prejemali tako v okviru adjuvantnega zdravljenja kot v okviru zdravljenja metastaz, in sicer v odmerkih od 300 mg do
• The treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).
• zdravljenje odraslih bolnikov z neresektabilnimi in/ali metastatskimi malignimi gastrointestinalnimi stromalnimi tumorji (GIST), pozitivnimi na Kit (CD 117);
See section 4.
Preglednica 7
1 Pneumonia was reported most commonly in patients with transformed CML and in patients with
1 O pljučnici so najpogosteje poročali pri bolnikih s transformacijo KML in pri bolnikih z GIST.
Study 0102 38-month data Myeloid blast crisis (n=260) % of patients (CI95%)
Študija 0102 podatki pri 38 mesecih mieloidna blastna kriza (n = 260)
There is limited experience in children with Ph-positive ALL and very limited experience in children with MDS/MPD, DFSP, GIST and HES/CEL.
Izkušenj pri otrocih s Ph pozitivno ALL je malo, pri otrocih z MDS/MPD, DFSP
If you forget to take Imatinib Teva B.V. - If you forget a dose, take it as soon as you remember.
Če pozabite vzeti odmerek, ga vzemite takoj, ko se spomnite.
Imatinib Teva is also a treatment for adults and children for: - Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph-positive ALL).
je tudi zdravilo za odrasle in otroke: - z akutno limfoblastno levkemijo s prisotnim kromosomom Philadelphia (Ph pozitivna
Prednisolone 60 mg/m oral, days 1-5
prednizolon 60 mg/m peroralno, 1.-5. dan
MTX 12 mg intrathecal, day 1 DEX 10 mg/m2 oral, days 6-7, 13-16;
MTX 12 mg intratekalno, 1. dan DEX 10 mg/m2 peroralno, 6.-7., 13.-16. dan;
Haematological experts in the management of this disease should supervise the therapy throughout all phases
V vseh fazah naj zdravljenje nadzira hematolog, strokovnjak za vodenje te bolezni.
There was no change in the kinetics of imatinib on repeated dosing, and accumulation was 1.5-2.5-fold at steady state when dosed once daily.
Pri ponovnem odmerjanju se kinetika imatiniba ni spreminjala, kopičenje pa je bilo pri enem odmerku na dan v stanju dinamičnega
Patients should be tested for HBV infection before initiating treatment with Imatinib Teva B.V.
Bolnike je treba pred začetkom zdravljenja z zdravilom Imatinib Teva B.V.
DEX 10 mg/m2 oral, days 6-7, 13-16;
DEX 10 mg/m2 peroralno, 6.-7., 13.-16. dan;
Based on preliminary population pharmacokinetic analysis in GIST patients, there were three variables (albumin, WBC and bilirubin) found to have a statistically significant relationship with imatinib pharmacokinetics.
(albumin, WBC in bilirubin) ugotovili, da so statistično signifikantno povezane s farmakokinetiko imatiniba.
Study AAU02 Induction therapy (de novo Ph+ ALL) Daunorubicin 30 mg/m2 i.v., days 1-3, 15-16;
Študija AAU02 Indukcijsko zdravljenje daunorubicin 30 mg/m2 i.v., 1.-3., 15.-16. dan;
Triple IT therapy (age-adjusted): days 1 and 22 VP-16 (100 mg/m2/day, IV): days 22-26
zdravljenje (prilagojeno na starost): 1. in 22. dan VP-16 (100 mg/m2/dan, i.v.
MTX 15 mg intrathecal, day 1 DEX 10 mg/m2 oral, days 1-5;
MTX 15 mg intratekalno, 1. dan DEX 10 mg/m2 peroralno, 1.-5. dan;
Traces of the dissolved tablets may be left behind in the glass.
Sledove raztopljenih tablet lahko
For doses of 400 mg and above (see dosage recommendation below) a 400 mg film-coated tablet is available.
Za odmerke 400 mg in več (glejte spodaj navedeno priporočeno odmerjanje) so na voljo 400 mg
Imatinib Teva B.V. can reduce the number of white blood cells, so you might get infections more easily.
vam lahko zmanjša število belih krvnih celic, zato lahko laže pride do okužbe,
• Chest pain, irregular heart rhythm (signs of heart problems).
• bolečine v prsnem košu, neredno bitje srca (znaki težav s srcem),
12-month treatment arm % (CI)
preživetje brez ponovitve bolezni skupina z 12-mesečnim zdravljenjem % (IZ)
The no observed effect level (NOEL) for both the maternal animals and the F1 generation was 15 mg/kg/day (one quarter of the maximum human dose of 800 mg).
tako na samice-matere kot na generacijo F1 je bil 15 mg/kg/dan (ena četrtina največjega odmerka za
All patients achieved complete haematological response, cytogenetic response and/or
Pri vseh bolnikih je prišlo do popolnega hematološkega odziva, do citogenetičnega odziva in/ali do kliničnega odziva.
Therefore, close monitoring of growth in children under imatinib treatment is recommended (see section
Zato je pri otrocih, ki prejemajo imatinib, priporočeno natančno spremljanje njihove rasti (glejte poglavje 4.8).
The recommended dose of Imatinib Teva B.V. is 400 mg/day for adult patients with MDS/MPD.
pri odraslih bolnikih z MDS/MPD je 400 mg/dan.
Figure 1 Kaplan-Meier estimates for primary recurrence-free survival endpoint (ITT population)
Ocena primarnega cilja opazovanja preživetja brez ponovitve bolezni po Kaplan Meierjevi metodi (populacija z namenom zdravljenja -ITT)
Non transparent orange capsules with black marking 7629 on capsule body and black marking TEVA on capsule cap.
Neprozorna oranžna kapsula, s črno oznako 7629 na telesu kapsule in s črno oznako TEVA na pokrovčku kapsule.
There are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival.
Razen za na novo diagnosticirano KML v kronični fazi ni kontroliranih kliničnih preskušanj, ki bi dokazovala klinično koristnost, na primer izboljšanje bolezenskih simptomov ali povečano preživetje.
Total bilirubin: = 1.5 ULN AST: >ULN (can be normal or <ULN if total bilirubin is >ULN)
AST: > IULN (lahko je normalna ali < IULN, če je celotni bilirubin > IULN) celotni bilirubin: > 1,5-3,0 IULN AST: kakršnakoli celotni bilirubin: > 3-10 IULN AST: kakršnakoli
Substances that are inducers of CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, fosphenytoin, primidone or Hypericum perforatum, also known as St. John's Wort) may significantly reduce exposure to imatinib, potentially increasing the risk of therapeutic failure.
Snovi, ki inducirajo aktivnost CYP3A4 (na primer deksametazon, fenitoin, karbamazepin, rifampicin, fenobarbital, fosfenitoin, primidon ali Hypericum perforatum, znan tudi pod imenom šentjanževka), lahko znatno zmanjšajo izpostavljenost imatinibu in s tem potencialno povečajo tveganje za neuspešnost zdravljenja.
If your daily dose is 800 mg (8 tablets), you should take 4 tablets in the morning and 4 tablets in
Če je vaš dnevni odmerek 800 mg (8 tablet), morate vzeti 4 tablete zjutraj in 4 tablete zvečer.
Hepatic insufficiency: Imatinib is mainly metabolised through the liver.
Imatinib se presnavlja predvsem v jetrih.
Non transparent orange capsules with black marking 7630 on capsule body and black marking TEVA on capsule cap.
Neprozorna oranžna kapsula, s črno oznako 7630 na telesu in s črno oznako TEVA na pokrovčku kapsule.
The adult patients reported in the published literature were treated with either 400 mg (4 cases) or 800 mg (1 case) imatinib daily.
Odrasli bolniki, o katerih so pisali v objavljeni literaturi, so bili zdravljeni z odmerki bodisi 400 mg (v 4 primerih) ali pa 800 mg (v 1 primeru) imatiniba na dan. Do odziva je prišlo pri petih (5) bolnikih, pri 3 do popolnega in pri 2 do delnega.
Dose increases from 340 mg/m2 daily to 570 mg/m2 daily (not to exceed the total dose of 800 mg) may be considered in children in the absence of severe adverse drug reaction and severe non-leukaemia-related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory haematological response after at least 3 months of treatment; failure to achieve a cytogenetic response after 12 months of treatment; or loss of a previously achieved haematological and/or cytogenetic response.
mg) pride v poštev pri otrocih, ki nimajo hudih neželenih učinkov na zdravilo in hude nevtropenije ali trombocitopenije, ki bi bila povezana z levkemijo, in sicer v sledečih okoliščinah: napredovanje bolezni (kadarkoli); odsotnost zadovoljivega hematološkega odziva po najmanj 3 mesecih zdravljenja; odsotnost citogenetičnega odziva po 12 mesecih zdravljenja; ali izguba že prej doseženega hematološkega ali citogenetičnega odziva ali obojega.
The dose is 800 mg per day (2 capsules), to be taken as one capsule in the morning and a second capsule in the evening.
Odmerek je 800 mg na dan (2 kapsuli), ki ga vzamete kot eno kapsulo zjutraj in eno kapsulo
A second multicentre, open label phase III study (SSG XVIII/AIO) compared 400 mg/day imatinib 12 months treatment vs. 36 months treatment in patients after surgical resection of GIST and one of the following: tumour diameter > 5 cm and mitotic count > 5/50 high power fields (HPF); or tumour diameter > 10 cm and any mitotic count or tumour of any size with mitotic count > 10/50 HPF or tumours ruptured into the peritoneal cavity.
GIST z eno od naslednjih možnosti: premer tumorja > 5 cm in število mitoz > 5/50 v vidnem polju mikroskopa pri veliki povečavi (HPF - high power fields) ali premer tumorja > 10 cm in kakršnokoli število mitoz ali kakršnakoli velikost tumorja in število mitoz > 10/50 HPF ali pa razpok tumorja v peritonealno votlino.
The age of these patients ranged from 2 to 16 years and imatinib was given at dose 300 mg/m2 daily or doses ranging from 200 to 400
Ti bolniki so bili stari od 2 do 16 let, imatinib pa so prejemali v odmerku 300 mg/m2 na dan ali v odmerkih od 200 mg do 400 mg na dan.
Description of selected adverse reactions:
otekanje sklepov občasni:
Pack sizes of 30x1 or 90x1 film-coated tablets in perforated unit dose blisters.
Škatle, ki vsebujejo po 30x1 ali 90x1 filmsko obloženih tablet v perforiranem pretisnem omotu za
In children and adolescents, Imatinib Teva B.V. can be used in different phases of the disease (chronic, accelerated phase and blast crisis).
uporablja za zdravljenje vseh faz te bolezni (kronični, pospešeni fazi in blastni krizi).
CML (CML-AP and CML-BC) than in patients with chronic CML.
KML (kronična mieloična levkemija v pospešeni fazi: KML-AP in kronična mieloična levkemija v blastni krizi: KML-BC) kot pri bolnikih s kroničnim potekom KML.
Headache2
jemati
The usual starting dose is 600 mg to be taken as one capsule of 400 mg plus 2 capsules of 100 mg
Običajni začetni odmerek je 600 mg, ki ga vzamete kot eno kapsulo po 400 mg in še 2 kapsuli
When and how to take Imatinib Teva B.V. - Take Imatinib Teva B.V. with a meal.
Kdaj in kako jemati zdravilo Imatinib Teva B.V.
There is very limited experience in children with MDS/MPD, DFSP, GIST
Izkušnje pri otrocih z MDS/MPD, DFSP in HES/CEL so zelo omejene.
Herpes zoster, herpes simplex, nasopharyngitis, pneumonia1, sinusitis, cellulitis, upper respiratory tract infection, influenza, urinary tract
Preglednica 1 Preglednica neželenih učinkov herpes zoster, herpes simpleks, nazofaringitis, pljučnica1, sinuzitis, flegmona, okužba zgornjih dihal, gripa, okužba sečil, gastroenteritis, sepsa redki:
Pack sizes of 20x1, 60x1, 120x1 or 180x1 film-coated tablets in perforated unit dose blisters.
Škatle, ki vsebujejo po 20x1, 60x1, 120x1 ali 180x1 filmsko obloženih tablet v perforiranem pretisnem omotu za posamezne odmerke.
Imatinib Teva B.V. 400 mg hard capsules are non-transparent orange capsules with black marking 7630 on capsule body and black marking TEVA on capsule cap.
400 mg trde kapsule so neprozorne oranžne kapsule s črno oznako 7630 na telesu in s črno oznako TEVA na pokrovčku kapsule.
In two clinical studies (study B2222 and an intergroup study S0033) the daily dose of imatinib was escalated to 800 mg in patients progressing at the lower daily doses of 400 mg or 600 mg.
V dveh kliničnih študijah (študija B2222 in študija med skupinami S0033) so pri bolnikih, pri katerih je pri manjših odmerkih 400 mg ali 600 mg na dan, bolezen napredovala, zvečali odmerek imatiniba na 800 mg na dan. Odmerek so zvečali na 800 mg na dan pri vsega skupaj 103 bolnikih; po zvečanju odmerka je 6 bolnikov doseglo delni odziv, 21 pa stabilizacijo svoje bolezni, kar je pomenilo celotno klinično koristnost 26 %.
9 Musculoskeletal pain during treatment with imatinib or after discontinuation has been observed in
9 V obdobju trženja zdravila so opažali mišično-skeletne bolečine med zdravljenjem z imatinibom ali po prekinitvi zdravljenja.
The dose is 800 mg per day (2 tablets), to be taken as one tablet in the morning and a second tablet in the evening.
Odmerek je 800 mg na dan (2 tableti), ki ga vzamete kot eno tableto zjutraj in eno tableto
• Mouth ulcers.
(imenovane eozinofilci).
- if you are taking the medicine levothyroxine because your thyroid has been removed.
- če imate ali ste kdaj imeli težave z jetri, ledvicami ali srcem; - če jemljete zdravilo levotiroksin, ker so vam odstranili ščitnico.
Tumour lysis syndrome
Limfoidna blastna kriza
The risk of recurrence was thus reduced by approximately 89% as compared with placebo (hazard ratio = 0.113 [0.049-0.264]).
Tveganje za ponovitev bolezni je bilo torej zmanjšano za približno 89% v primerjavi s placebom (razmerje tveganj
For adult patients with relapsed or refractory Ph+ALL imatinib monotherapy at 600 mg/day is safe, effective and can be given until disease progression occurs.
Za odrasle bolnike z relapsom ali neodzivno Ph+ ALL je imatinib kot monoterapija v odmerku 600
(1 h), days 28-31, 35-38, 42-45; 6-MP 60 mg/m2 oral, days 26-46
(1 ura), 28.-31., 35.-38., 42.-45. dan; 6-MP 60 mg/m2 peroralno, 26.-46. dan DEX 10 mg/m2 peroralno, 1.-5. dan; vindezin 3 mg/m2 i.v., 1. dan;
The dose can be reduced if not tolerated (see section 4.2 and 5.2).
če ga bolnik ne prenaša dobro (glejte poglavji 4.2 in 5.2).
If your daily dose is 800 mg (8 capsules), you should take 4 capsules in the morning and 4
Če je vaš dnevni odmerek 800 mg (8 kapsul), morate vzeti 4 kapsule
Very common:
pogosti:
ANC ≥ 1 x 109/l and platelets ≥ 20 x 109/l,
NEL enaki kriteriji kot za CHR, a ANC ≥ 1 x 109/l in trombociti ≥ 20 x 109/l
• Muscle spasms with a fever, red-brown urine, pain or weakness in your muscles (signs of muscle
• bolečine v želodcu z občutkom slabosti s siljenjem na bruhanje (navzea), • mišični spazmi z vročino, rdeče-rjavo obarvan urin, boleče ali oslabele mišice (znaki težav z
The recommended dose of Imatinib Teva B.V. is 600 mg/day for adult patients with Ph+ ALL.
pri odraslih bolnikih s Ph+ ALL je 600 mg/dan.
Depression, libido decreased, anxiety
hiperkaliemija, hipomagneziemija nespečnost depresija, zmanjšan libido, anksioznost zmedenost glavobol2
Rash pustular, contusion, sweating increased, urticaria, ecchymosis, increased tendency to bruise, hypotrichosis, skin hypopigmentation, dermatitis exfoliative, onychoclasis, folliculitis, petechiae, psoriasis, purpura, skin hyperpigmentation, bullous eruptions
urtikarija, ekhimoza, nagnjenost k podplutbam, hipotrihoza, hipopigmentacija kože, eksfoliativni dermatitis, lomljenje nohtov, folikulitis, petehije, psoriaza, purpura, hiperpigmentacija kože, bulozne erupcije akutna febrilna nevtrofilna dermatoza (Sweetov sindrom), sprememba barve nohtov,
The usual starting dose is 600 mg to be taken as one tablet of 400 mg plus 2 tablets of 100 mg once a
Začetni odmerek je 600 mg, ki ga vzamete kot eno tableto po 400 mg in še 2 tableti po 100 mg enkrat na dan.
Psychiatric disorders Common:
anoreksija občasni:
If your daily dose is 800 mg (2 tablets), you should take one tablet in the morning and a second
Če je vaš dnevni odmerek 800 mg (2 tableti), morate vzeti 1 tableto zjutraj in 1 tableto zvečer.
Vindesine 3 mg/m2 i.v., day 1;
VCR 1,3 g/m2 i.v., 1. dan;
Blood creatinine increased, blood creatine phosphokinase increased, blood lactate dehydrogenase increased, blood alkaline phosphatase
bolečine v prsnem košu, slabo počutje zvečanje telesne mase zmanjšanje telesne mase zvišana vrednost kreatinina v krvi, zvišana vrednost kreatin-kinaze v krvi, zvišana vrednost laktat-dehidrogenaze v krvi, zvišana vrednost alkalne fosfataze v krvi zvišana vrednost amilaze v krvi
Table 4 Chemotherapy regimen used in combination with imatinib in study I2301
Preglednica 4 Kemoterapevtske sheme, uporabljene v kombinaciji z imatinibom v
Your doctor will tell you exactly how many tablets of Imatinib Teva B.V. to take.
Zdravnik vam bo natančno povedal, koliko tablet zdravila Imatinib Teva B.V.
The usual starting dose is 600 mg to be taken as 6 tablets once a day.
Običajni začetni odmerek je 600 mg, ki ga vzamete kot 6 tablet enkrat na dan.